3 lectures · 127 items
Heart failure is common in people with atrial fibrillation detected during screening
DECAF - A cup of coffee a day could keep atrial fibrillation from coming backEducation, exchange, guidance and interaction during EPCCS Summit 2019Slides | Update on stroke prevention in atrial fibrillationUpdate on stroke prevention in atrial fibrillation
Погоджена настанова EPCCS щодо профілактики інсульту при фібриляції передсердь в системі надання первинної медичної допомогиPrevencia cievnej mozgovej príhody u pacientov s fibriláciou predsiení
Atrial Fibrillation Management: What do the guidelines say and what are the implications for primary care?
EPCCS Guidance Documents
EPCCS consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary careA Scientific Statement From the American Heart Association.
The American Heart Association highlights the substantial clinical and public health burden of antithrombotic undertreatment in patients with atrial fibrillation, venous thromboembolism, or…
ablating low-voltage areas on top of pulmonary vein isolation does not significantly reduce recurrence of persistent atrial fibrillation overall, but does in the half of patients who have such areas
Presented in LBS.04 at AHA 2026 (Sunday 8 November) and published simultaneously in JAMA. COAST-AF (Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation) is a…
An updated meta-analysis of six randomized trials (7,028 patients) comparing percutaneous left atrial appendage closure (LAAC) with oral anticoagulation in nonvalvular atrial fibrillation found…
Competing Adverse Events in a Nationwide Cohort.
In a nationwide Finnish cohort of 1,502 patients with atrial fibrillation and prior intracranial bleeding, the 1-year risk of ischemic stroke fell from 4.1% with no anticoagulation to 0.7% with DOACs…
a randomised, double-blind, sham-controlled, multicentre trial.
In the double-blind, sham-controlled PVI-SHAM-AF trial, 262 patients with symptomatic paroxysmal or persistent atrial fibrillation were randomised to catheter ablation or a sham procedure. At six…
from episode burden to net clinical benefit.
This narrative review synthesizes evidence from the ARTESiA and NOAH-AFNET 6 trials regarding anticoagulation for device-detected atrial high-rate episodes and subclinical atrial fibrillation. While…
Researchers developed and externally validated FIND-AF 2.0, a machine learning model using electronic health records to identify patients at high risk of developing atrial fibrillation (AF). In a…
the safety and efficacy of oral anticoagulants in atrial fibrillation patients with prior intracranial haemorrhage: a systematic review and meta-analysis.
A systematic review and meta-analysis evaluated direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation and a history of intracranial haemorrhage…
milvexian prevents no events after an acute coronary syndrome and does not bleed less, a blow to the factor XI hypothesis in ACS
The full results of the trial stopped for futility in November 2025: 14,194 patients within 7 days of an ACS with at least two risk factors, milvexian 25 mg twice daily or placebo on top of…
prasugrel or ticagrelor with a DOAC after infarction in atrial fibrillation triples major bleeding, the trial was stopped early
Randomised trial stopped early for safety after 602 of 1,474 planned patients with AF and myocardial infarction: DOAC plus one month of prasugrel or ticagrelor versus DOAC plus clopidogrel (with…
a DOAC protects patients with atrial fibrillation and a single stroke risk factor, without excess major bleeding
The first randomised trial in the guideline grey zone: 1,803 Korean patients with AF and a CHA2DS2-VASc score of 1 (men) or 2 (women) were randomised to apixaban or rivaroxaban versus no…
the hypothesis, the promise and the LIBREXIA ACS lesson
Factor XI inhibition promises antithrombotic effect without the bleeding cost, but the field keeps hitting reality: after asundexian, the 14,000-patient LIBREXIA ACS trial of milvexian was halted for…
